Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with Oesophageal Squamous Cell Cancer By Ogkologos - April 23, 2025 766 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a biomarker analysis from the RATIONALE-302 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug April 23, 2018 Durvalumab Extends Lives of People with Early-Stage Small Cell Lung Cancer June 25, 2024 Efficacy of Sintilimab in the Adjuvant Treatment for Patients with Resected,... January 26, 2024 Former WNBA Player, Current Georgia Tech Coach Tasha Butts Diagnosed with... December 14, 2021 Load more HOT NEWS Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine... Progress in Treating GI Cancers Through Molecular Testing: The 2021 Advance... FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or...
